^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cam1615SS1

    i
    Other names: mesothelin-targeted TriKE, cam1615SS1, MSLN-targeted TriKE
    Associations

    News

    Trials
    Company:
    GT Biopharma
    Drug class:
    NK cell stimulant, Mesothelin inhibitor, IL-15 stimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. (PubMed, Front Immunol)
    Importantly, TriKE triggered NK cell responses from patients at all stages of disease and treatment, suggesting TriKE can enhance current therapies. These pre-clinical studies suggest mesothelin-targeted TriKE has the potential to overcome the immunosuppressive environment of NSCLC to treat disease.
    Journal • Trispecific
    |
    MSLN (Mesothelin) • CD14 (CD14 Molecule) • IL15 (Interleukin 15)
    |
    cam1615SS1